These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 23677114)

  • 21. Update to an open-label clinical trial of vismodegib as neoadjuvant before surgery for high-risk basal cell carcinoma (BCC).
    Kwon GP; Ally MS; Bailey-Healy I; Oro AE; Kim J; Chang AL; Aasi S; Tang JY
    J Am Acad Dermatol; 2016 Jul; 75(1):213-5. PubMed ID: 27317518
    [No Abstract]   [Full Text] [Related]  

  • 22. Targeting the hedgehog pathway to treat basal cell carcinoma.
    Geeraert P; Williams JS; Brownell I
    J Drugs Dermatol; 2013 May; 12(5):519-23. PubMed ID: 23652945
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enlarging Multiple Neoplastic Skin Growths.
    Feinstein EG; Zhou M; Setabutr P
    JAMA Ophthalmol; 2016 Mar; 134(3):337-8. PubMed ID: 26767432
    [No Abstract]   [Full Text] [Related]  

  • 24. Vismodegib for the treatment of basal cell carcinoma: results and implications of the ERIVANCE BCC trial.
    Dessinioti C; Plaka M; Stratigos AJ
    Future Oncol; 2014 May; 10(6):927-36. PubMed ID: 24941979
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An investigator-initiated open-label clinical trial of vismodegib as a neoadjuvant to surgery for high-risk basal cell carcinoma.
    Ally MS; Aasi S; Wysong A; Teng C; Anderson E; Bailey-Healy I; Oro A; Kim J; Chang AL; Tang JY
    J Am Acad Dermatol; 2014 Nov; 71(5):904-911.e1. PubMed ID: 24929884
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Follicular and cystic regression of locally advanced basal cell carcinoma following short-term neoadjuvant vismodegib therapy.
    Mohr M; Schumacher N; Zillikens D; Terheyden P
    J Dtsch Dermatol Ges; 2017 Oct; 15(10):1031-1033. PubMed ID: 28898543
    [No Abstract]   [Full Text] [Related]  

  • 27. Photodynamic therapy for treatment of multiple lesions on the scalp in nevoid basal cell carcinoma syndrome: case report.
    Neves DR; Ramos DG; Magalhães GM; Rodrigues Rda C; Souza JB
    An Bras Dermatol; 2010; 85(4):545-8. PubMed ID: 20944918
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gorlin Syndrome, Vulvar Basal Cell Carcinomas, Vismodegib, and Lichen Sclerosus: From the ISSVD Case Consultation Committee.
    Kirkpatrick E; Dobriansky D; Scurry J
    J Low Genit Tract Dis; 2016 Jul; 20(3):e40-1. PubMed ID: 27105331
    [No Abstract]   [Full Text] [Related]  

  • 29. [Not Available].
    Basset-Seguin N
    Ann Dermatol Venereol; 2018 Nov; 145 Suppl 5():VS36-VS41. PubMed ID: 30477683
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Vismodegib for basal cell carcinoma: targeted therapy in case of locally advanced or metastasised disease].
    Reinders MG; Terra JB; Reyners AK; Aarts MJ; de Haas ER; Mosterd K
    Ned Tijdschr Geneeskd; 2016; 160():D187. PubMed ID: 28000572
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Photodynamic therapy for a nevoid basal cell carcinoma syndrome].
    Hanneken S; Sterzinger AA; Schulte KW; Reifenberger J
    Hautarzt; 2005 Apr; 56(4):363-4. PubMed ID: 15750676
    [No Abstract]   [Full Text] [Related]  

  • 32. Vismodegib resistant mutations are not selected in multifocal relapses of locally advanced basal cell carcinoma after vismodegib discontinuation.
    Ighilahriz M; Benfodda M; Sharpe H; Soufir N; Mourah S; Dumaz N; Battistella M; Savina A; Bouquet F; Nikolaev S; Basset-Seguin N
    J Eur Acad Dermatol Venereol; 2019 Nov; 33(11):e422-e424. PubMed ID: 31187903
    [No Abstract]   [Full Text] [Related]  

  • 33. [Vismodegib in metastasized basal cell carcinoma].
    Reinders MG; Dirix L; Mosterd K; van Doorn R
    Ned Tijdschr Geneeskd; 2013; 157(12):A6011. PubMed ID: 23515044
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Analysis of basal cell carcinomas' histological subtypes and relative response to vismodegib in six patients diagnosed with Gorlin-Goltz syndrome: A retrospective study.
    Scotti B; Melotti B; Baraldi C; Comito F; Venturi F; Lambertini M; Dika E
    J Eur Acad Dermatol Venereol; 2024 Apr; 38(4):e339-e341. PubMed ID: 37909360
    [No Abstract]   [Full Text] [Related]  

  • 35. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib.
    Chang AL; Solomon JA; Hainsworth JD; Goldberg L; McKenna E; Day BM; Chen DM; Weiss GJ
    J Am Acad Dermatol; 2014 Jan; 70(1):60-9. PubMed ID: 24189279
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of multiple unresectable basal cell carcinomas from Gorlin-Goltz syndrome: a case report.
    Ojevwe FO; Ojevwe CD; Zacny JP; Dudek AZ; Lin A; Kohlitz P
    Anticancer Res; 2015 Mar; 35(3):1777-81. PubMed ID: 25750342
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Two different scenarios of squamous cell carcinoma within advanced Basal cell carcinomas: cases illustrating the importance of serial biopsy during vismodegib usage.
    Zhu GA; Sundram U; Chang AL
    JAMA Dermatol; 2014 Sep; 150(9):970-3. PubMed ID: 24740281
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mesenteric cysts in naevoid basal cell carcinoma syndrome: a mimic of metastatic disease.
    Rajan N; Brown S; Ward S; Hainsworth P; Hodgkinson P; Pieniazek P; Husain A; Plummer R
    Br J Dermatol; 2016 Mar; 174(3):684-5. PubMed ID: 26473628
    [No Abstract]   [Full Text] [Related]  

  • 39. Vismodegib in basal cell carcinoma.
    Amaria RN; Bowles DW; Lewis KD; Jimeno A
    Drugs Today (Barc); 2012 Jul; 48(7):459-67. PubMed ID: 22844657
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Unique Tumor Heterogeneity Within a Single Locally Advanced Basal Cell Carcinoma Resulting in a Partial Response Despite Continuous Vismodegib Treatment.
    Nayyar PM; Chang ALS; Sarin K; Ratner D
    Dermatol Surg; 2019 Apr; 45(4):608-610. PubMed ID: 30045109
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.